(FILE 'HOME' ENTERED AT 09:48:50 ON 03 OCT 2003)

FILE 'MEDLINE,	CANCERLIT, LIF	ESCI, SCISEAR	RCH, EMBASE,	BIOSIS,	CAPLUS'
ENTERED AT 09	:49:06 ON 03 OCT	2003			

E GUIDA M/AU

L1 644 SEA "GUIDA M"/AU OR "GUIDA MARCO"/AU E HALL J/AU

L2 2902 SEA "HALL J"/AU

E HALL JEFF/AU

L3 36 SEA "HALL JEFF"/AU E PETROS W/AU

L4 393 SEA "PETROS W"/AU OR "PETROS W P"/AU OR "PETROS WILLIAM"/AU

OR

"PETROS WILLIAM P"/AU

E VREDENBURGH J/AU

L5 467 SEA "VREDENBURGH J"/AU OR "VREDENBURGH J J"/AU OR "VREDENBURGH

JAMES"/AU OR "VREDENBURGH JAMES J"/AU E COLVIN O M/AU

- L6 713 SEA "COLVIN O"/AU OR "COLVIN O M"/AU OR "COLVIN OLIVER M"/AU E MARKS J M/AU
- L7 282 SEA "MARKS J M"/AU E MARKS J R/AU
- L8 377 SEA "MARKS J R"/AU E MARKS JEFFREY R/AU
- L9 101 SEA "MARKS JEFFREY R"/AU
- L10 13485 SEA (CYP3A4 OR CYP 3A4 OR P450 3A4 OR P 450 3A4 OR CYPIIIA4 OR CYP IIIA4 OR P450IIIA4 OR P450 IIIA4 OR P 450 IIIA4)
- L11 257 SEA L10 AND (POLYMORPHISM OR VARIANT OR MUTATION OR ALLEL####)

AND(PROMOTER OR UPSTREAM OR REGULAT######)

- L12 416 SEA (CYP3P5 OR CYP 3A5 OR P450 3A5 OR P 450 3A5 OR CYPIIIA5 OR CYP IIIA5 OR P450IIIA5 OR P450 IIIA5 OR P 450 IIIA5)
- L13 28 SEA L12 AND (POLYMORPHISM OR VARIANT OR MUTATION OR ALLEL####)

AND(PROMOTER OR UPSTREAM OR REGULAT######)

L14 2878 SEA (GSTM1 OR GLUTATHIONE S TRANSFERASE M1 OR GLUTATHIONE

STRANSFERASE M1) AND NULL

- L15 6 SEA (L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L8 OR L9) AND (L11 OR L13 OR L14)
- L16 4 DUP REM L15 (2 DUPLICATES REMOVED)
- L17 27 SEA (CYCLOPHOSPHAMIDE) AND (L11 OR L12 OR L14)
- L18 17 DUP REM L17 (10 DUPLICATES REMOVED)
- L19 21 SEA (CYCLOPHOSPHAMIDE) AND (L11 OR L13 OR L14)

L20	11 DUP REM L19 (10 DUPLICATES REMOVED)
L21	6 SEA (CARMUSTINE OR BCNU OR BICNU OR NITROSOUREA) AND (L11
OR	
	L13 OR L14)
L22	5 DUP REM L21 (1 DUPLICATE REMOVED)
L23	46 SEA L11 AND (SUBSTRATE OR CHEMOTHERAP##### OR AGENT)
L24	24 DUP REM L23 (22 DUPLICATES REMOVED)
L25	7 SEA L13 AND (SUBSTRATE OR CHEMOTHERAP###### OR AGENT)
L26	5 DUP REM L25 (2 DUPLICATES REMOVED)
L27	189 SEA L14 AND (SUBSTRATE OR CHEMOTHERAP###### OR AGENT)
L28	72 DUP REM L27 (117 DUPLICATES REMOVED)
L29	66 SEA L11 AND (HOMOZYGOUS OR HETEROZYGOUS)
L30	16 SEA L11 AND RESTRICTION
L31	8 SEA L29 AND L30
L32	3 DUP REM L31 (5 DUPLICATES REMOVED)
L33	11 SEA L13 AND (HOMOZYGOUS OR HETEROZYGOUS)
L34	2 SEA L13 AND RESTRICTION
L35	0 SEA L33 AND L34
L36	2 DUP REM L34 (0 DUPLICATES REMOVED)
L37	6 DUP REM L33 (5 DUPLICATES REMOVED)
L38	0 SEA L13 AND 147
L39	650 SEA L14 AND (HOMOZYGOUS OR HETEROZYGOUS)
L40	215 SEA L14 AND RESTRICTION
L41	33 SEA L39 AND L40
L42	12 DUP REM L41 (21 DUPLICATES REMOVED)

WEST Search History

DATE: Friday, October 03, 2003

Set Name Query side by side		Hit Count Set Name result set	
DB = U	SPT,PGPB,DWPI; PLUR=YES; OP=ADJ		
L11	L10 not (18 or 19)	16	L11
L10	(15 or 16 or 17) and (substrate or chemotherap\$6 or agent)	20	L10
L9	(15 or 16 or 17) and (carmustine or benu or bienu or nitrosourea)	3	L9
L8	(15 or 16 or 17) and cyclophosphamide	4	L8
L7	(gstm1 or glutathione s transferase m1 or glutathione stransferase m1)same(null)	6	L7
L6	14 same (polymorphism or mutation or variant or allel\$4) same (promoter or upstream or regulator\$5)	7	L6
L5	13 same (polymorphism or mutation or variant or allel\$4) same (promoter or upstream or regulator\$5)	17	L5
L4	(cyp3a5 or cyp 3a5 or p450 3a5 or p 450 3a5 or cypiiia5 or cyp iiia5 or p450iiia5 or p450 iiia5 or p 450 iiia5)	59	L4 (
L3	(cyp3a4 or cyp 3a4 or p450 3a4 or p 450 3a4 or cypiiia4 or cyp iiia4 or p450iiia4 or p450 iiia4 or p 450 iiia4)	439	L3
L2	(guida-m\$.in. or hall-j\$.in. or petros-w\$.in. or vredenburgh-j\$.in. or colvin-o\$.in. or marks-j\$.in.)	2609	L2
L1	'DUKE UNIVERSITY INC.'!	0	L1

END OF SEARCH HISTORY

National Library of Medicine - Medical Subject Headings

2003 MeSH

MeSH Descriptor Data

Return to Entry Page

MeSH Heading	Cyclophosphamide
Tree Number	D02.455.526.728.650.730.243
Tree Number	D02.705.670.243
Scope Note	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active <u>ALDOPHOSPHAMIDE</u> . It is used in the treatment of lymphomas, leukemias, etc. Its side effect, <u>ALOPECIA</u> , has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Entry Term	B-518
Entry Term	Cyclophosphamide Monohydrate
Entry Term	Cyclophosphamide, (+-)-Isomer
Entry Term	Cyclophosphamide, (R)-Isomer
Entry Term	Cyclophosphamide, (S)-Isomer
Entry Term	Cyclophosphane
Entry Term	Cytophosphan
Entry Term	Cytoxan
Entry Term	Endoxan
Entry Term	NSC-26271
Entry Term	Neosar
Entry Term	Procytox
Entry Term	Sendoxan
	AA AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME PD PK PO RE SD ST TO TU UR
Pharm. Action	Antineoplastic Agents, Alkylating
Pharm. Action	Antirheumatic Agents
Pharm. Action	Immunosuppressive Agents
Pharm. Action	<u>Mutagens</u>
CAS Type 1 Name	2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide

National Library of Medicine - Medical Subject Headings

2003 MeSH

MeSH Descriptor Data

Return to Entry Page

MeSH Heading	Carmustine
Tree Number	D02.654.692.247
Tree Number	D02.948.594.247
Scope Note	A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Entry Term	BCNU
	1,3-Bis(2-Chloroethyl)-1-Nitrosourea
Entry Term	BiCNU
Entry Term	FIVB
Entry Term	N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
Entry Term	
Allowable Qualifiers	AA AD AE AG AI AN BL CF CH CL CS CT DU EC HI IM IP ME PD PK PO RE SD ST TO TU UR
Pharm. Action	Antineoplastic Agents, Alkylating
CAS Type 1 Name	Urea, N,N'-bis(2-chloroethyl)-N-nitroso-
Registry Number	154-93-8
Previous Indexing	Alkylating Agents (1966-1971)
Previous Indexing	Nitroso Compounds (1966-1971)
Previous Indexing	<u>Urea</u> (1966-1971)
History Note	73(72)
Unique ID	D002330

MeSH Tree Structures